You have 9 free searches left this month | for more free features.

T-NK-LGL

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

CLL, SLL, HCL Trial in Dresden

Recruiting
  • CLL
  • +7 more
    • Dresden, Sachsen, Germany
      BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
    Apr 29, 2022

    Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

    Recruiting
    • Extranodal NK T Cell Lymphoma
    • NK-Cell Leukemia
    • Anti-CD56 CAR T
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Jul 10, 2023

    NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

    Not yet recruiting
    • NK-T-Cell Lymphoma, Extranodal
    • 4 cycles of ESA regimen with sandwiched radiotherapy
    • +2 more
    • Shanghai, Shanghai, China
      Ruijin Hospital
    Sep 29, 2023

    NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

    Not yet recruiting
    • NK-T-Cell Lymphoma, Extranodal
    • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
    • (no location specified)
    Mar 7, 2023

    nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

    Recruiting
    • nk/T-cell Lymphoma
    • +2 more
    • XPO1 inhibitor
    • Beijing, Haidian, China
      ChinaPLAGH
    Apr 18, 2023

    Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

    Not yet recruiting
    • Extranodal NK/T-cell Lymphoma
    • Sugemalimab
    • +4 more
    • (no location specified)
    Jan 17, 2023

    T-Cell and NK-Cell Tumor Trial

    Not yet recruiting
    • T-Cell and NK-Cell Neoplasm
      • (no location specified)
      Sep 28, 2023

      Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

      Not yet recruiting
      • Synovial Sarcoma
      • Fludarabine phosphate
      • +2 more
      • Houston, Texas
        MD Anderson Cancer Center
      Oct 9, 2023

      NK/T-cell Lymphoma Trial in Shanghai (Positron Emission Tomography/Magnetic Resonance (PET/MR))

      Not yet recruiting
      • NK/T-cell Lymphoma
      • Positron Emission Tomography/Magnetic Resonance (PET/MR)
      • Shanghai, Shanghai, China
        Ruijin Hospital
      Dec 14, 2022

      Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

      Not yet recruiting
      • Peripheral T Cell Lymphoma
      • Zhengzhou, Henan, China
        Henan cancer hospital
      Jun 2, 2023

      Lymphoma Trial (Tislelizumab)

      Not yet recruiting
      • Lymphoma
      • (no location specified)
      Jul 28, 2022

      Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

      Active, not recruiting
      • Extranodal NK/T Cell Lymphoma, Nasal Type
      • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
      • Guangdong, China
        Sun Yat-sen University Cancer Center
      Oct 10, 2022

      Lymphoma Trial in United States (Ruxolitinib)

      Recruiting
      • Lymphoma
      • Miami, Florida
      • +9 more
      Oct 5, 2022

      NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

      Not yet recruiting
      • NK/T Cell Lymphoma
      • +2 more
      • Guangzhou, Guangdong, China
      • +1 more
      Jan 12, 2023

      Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

      Recruiting
      • Peripheral T/NK Cell Lymphoma (R/R PTCL)
      • Houston, Texas
        MD Anderson Cancer Center
      Oct 19, 2022

      T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell Trial in Busan, Daegu (Busulfan, Fludarabine)

      Recruiting
      • T-cell Non-Hodgkin Lymphoma
      • Lymphoma, Extranodal NK-T-Cell
      • Busan, Korea, Republic of
      • +1 more
      Aug 17, 2022

      Aggressive NK Cell Leukemia Trial in Hiroshima (PPMX-T003)

      Recruiting
      • Aggressive NK Cell Leukemia
      • Hiroshima, Japan
        Hiroshima University Hospital
      May 9, 2023

      Acute Myeloid Leukemia in Children Trial in Saint Louis (CIML NK Cell Infusion, CD3+ T Cell Product Infusion)

      Recruiting
      • Acute Myeloid Leukemia in Children
      • CIML NK Cell Infusion
      • CD3+ T Cell Product Infusion
      • Saint Louis, Missouri
        Washington University School of Medicine
      Oct 26, 2022

      Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

      Active, not recruiting
      • Extranodal NK/T-cell Lymphoma
      • B-MAD chemotherapy
      • Bangkok, Thailand
        King Chulalongkorn Memorial Hospital
      May 7, 2022

      Lymphoma, Extranodal NK-T-Cell Trial in Shanghai (Pembrolizumab, Involved Field Radiation Therapy)

      Recruiting
      • Lymphoma, Extranodal NK-T-Cell
      • Shanghai, China
        Shanghai Rui-Jin Hospital
      Mar 29, 2022

      LGL Leukemia, CTCL Trial in United States (BNZ132-1-40)

      Completed
      • LGL Leukemia
      • CTCL
      • Duarte, California
      • +3 more
      May 24, 2021

      Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

      Completed
      • Mature T-Cell and NK-Cell Neoplasm
      • Hwasun-gun, Jeollanam-do, Korea, Republic of
        Chonnam National University Hwasun Hospital
      Jun 9, 2022

      T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

      Not yet recruiting
      • T-Cell Non-Hodgkin Lymphoma
      • +14 more
      • WU-CART-007
      • Saint Louis, Missouri
        Washington University School of Medicine
      Jan 17, 2023

      Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

      Not yet recruiting
      • Extranodal NK/T Cell Lymphoma
      • Nanjing, Jiangsu, China
        Hematological Department, People's Hospital of Jiangsu Province
      Jun 16, 2022